Moleculin Biotech MBRX is set to give its latest quarterly earnings report on Friday, 2024-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Moleculin Biotech will report an earnings per share (EPS) of $-2.44.
Investors in Moleculin Biotech are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
Overview of Past Earnings
In the previous earnings release, the company beat EPS by $0.61, leading to a 10.8% drop in the share price the following trading session.
Here's a look at Moleculin Biotech's past performance and the resulting price change:
| Quarter | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| EPS Estimate | -2.31 | -3.53 | -3.05 | -3.60 |
| EPS Actual | -1.70 | -2.02 | -5.09 | -2.85 |
| Price Change % | -11.0% | -0.0% | -14.000000000000002% | -5.0% |
Market Performance of Moleculin Biotech's Stock
Shares of Moleculin Biotech were trading at $2.36 as of November 06. Over the last 52-week period, shares are down 71.6%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release.
To track all earnings releases for Moleculin Biotech visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
